Medacta Group SA Reports Strong 2024 Results

Medacta Group SA has reported substantial financial growth for the fiscal year 2024, noting revenue of €590.6 million, a 16.2% increase in constant currency. This growth reflects significant expansion across all geographic areas, particularly in Europe, the Middle East, and Africa. The company's adjusted EBITDA increased by 19.4% to €160.2 million, resulting in a margin of 28.0% in constant currency.

Key advancements included the launch of innovative surgical solutions, such as the GMK SpheriKA knee implant and the NextAR Augmented Reality Surgical Platform, which contributed to revenue growth across product lines. Medacta also expanded its production capacity, with facilities in Switzerland growing in size and staffing levels rising globally.

The Board of Directors proposes a dividend increase to CHF 0.69 per share for 2024, up from CHF 0.55 the previous year. For 2025, Medacta projects revenue growth of 13% to 15% in constant currency and an adjusted EBITDA margin of around 27%, depending on market conditions.